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Abstract
Aim: Activation of the master energy-regulator AMP-activated protein kinase (AMPK) in the heart reduces the severity of
ischemia-reperfusion injury (IRI) but the role of AMPK in renal IRI is not known. The aim of this study was to determine
whether activation of AMPK by acute renal ischemia influences the severity of renal IRI.
Methods: AMPK expression and activation and the severity of renal IRI was studied in mice lacking the AMPK b1 subunit and
compared to wild type (WT) mice.
Results: Basal expression of activated AMPK, phosphorylayed at aThr172, was markedly reduced by 96% in AMPK-b12/2
mice. Acute renal ischaemia caused a 3.2-fold increase in a1-AMPK activity and a 2.5-fold increase in a2-AMPK activity
(P,0.001) that was associated with an increase in AMPK phosphorylation of the AMPK-a subunit at Thr172 and Ser485, and
increased inhibitory phosphorylation of the AMPK substrate acetyl-CoA carboxylase. After acute renal ischemia AMPK
activity was reduced by 66% in AMPK-b12/2 mice compared with WT. There was no difference, however, in the severity of
renal IRI at 24-hours between AMPK-b12/2 and WT mice, as measured by serum urea and creatinine and histological injury
score. In the heart, macrophage migration inhibitory factor (MIF) released during IRI contributes to AMPK activation and
protects from injury. In the kidney, however, no difference in AMPK activation by acute ischemia was observed between
MIF2/2 and WT mice. Compared with the heart, expression of the MIF receptor CD74 was found to be reduced in the
kidney.
Conclusion: The failure of AMPK activation to influence the outcome of IRI in the kidney contrasts with what is reported in
the heart. This difference might be due to a lack of effect of MIF on AMPK activation and lower CD74 expression in the
kidney.
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Introduction
AMPK is a ubiquitously expressed, energy-sensing kinase that is
activated during energy stress by an increase in cellular [AMP] [1].
When activated, AMPK acts to restore energy homeostasis by
phosphorylating multiple substrates to both activate pathways of
energy production, such as fatty acid oxidation, and to inhibit
energy consuming pathways such as protein synthesis and ion
transport [2]. AMPK exists as a heterotrimer with a catalytic a
subunit and regulatory b and c subunits [1]. Each of the subunits
has multiple isoforms (a1, a2, b1, b2, c1, c2, c3) leading to
multiple heterotrimer combinations [2]. In the ischemic heart the
effect of AMPK activation is reported to be beneficial by
preventing post-ischemic cardiac dysfunction, apoptosis, and
injury [3,4,5,6]. These studies, however, have been contradicted
by others, which showed that activation of AMPK in the ischemic
heart has either no effect [7] or increases apoptosis [8].
Contrasting with the heart, activation of AMPK in the ischemic
brain appears to worsen injury [9,10,11]. In the kidney, AMPK is
reported to be involved in a variety of physiological and
pathological processes including ion transport [12], podocyte
function [13] and diabetic renal hypertrophy [14]. AMPK is
rapidly activated by acute renal ischemia [15] but whether this has
an effect on the outcome the outcome of renal IRI is not known.
Stimulation of AMPK in the ischemic heart by macrophage
migration inhibitory factor (MIF) is reported to protect against
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myocardial ischemia-reperfusion injury (IRI) [6,16]. In contrast, it
is unknown whether MIF, which is widely expressed in the normal
kidney [17], contributes to AMPK activation by acute renal
ischemia.
The present study aims to determine the functional significance
of AMPK activation in acute renal ischemia by determining the
outcome of IRI in mice deficient for the AMPK b1 subunit
(AMPK-b12/2 mice). It also seeks to determine whether MIF
contributes to AMPK activation in acute renal ischemia as it does
in the heart.
Materials and Methods
Materials and reagents
Rabbit polyclonal antibodies against a1-AMPK, a2-AMPK,
b1-AMPK, b2-AMPK, c1-AMPK, c2-AMPK, pThr172a-AMPK
and p-ACC-Ser79 were produced as previously described [15,18].
A monoclonal Ab against MIF (ab 7207) was purchased from
Abcam (Cambridge, UK). A rabbit monoclonal antibody against
ACC1 was from Cell Signaling (MA, USA). A goat polyclonal
against CD74 (sc-5438) was purchased from Santa Cruz (CA,
USA). Secondary antibodies (swine-anti-rabbit-HRP, rabbit-anti-
mouse-HRP) were purchased from Dako (Carpinteria CA, USA).
Protein A-HRP was purchased from Amersham Pharmacia
(Uppsala, Sweden).
Animals
AMPK-b12/2 mice were generated on a C57Bl/6 background
as recently described [19]. AMPK-a12/2 mice were kindly
provided by Professor Benoit Viollet (IC, Institut Cochin
Universite´ Paris Descartes). Experiments using the AMPK
knockout strains were performed using littermate WT controls
from heterozygous mating. The MIF2/2 mice used for study are
on a C57Bl/6 background, as previously described [20]. Wild type
C57Bl/6 mice were from the Walter and Eliza Hall Institute
(Parkville, Vic).
Ethics statement
All animal procedures were performed in the animal facilities of
the Austin Hospital or St Vincent’s Hospital and were approved
by the animal ethics committees of these hospitals. All animal work
was conducted according to national and international ethical
guidelines.
Induction of acute renal ischemia
Mice were anaesthetized by intraperitoneal injection of
ketamine (85 mg/kg) and xylazine (15 mg/kg). The left kidney
was accessed by a midline laparotomy and acute renal ischemia
was induced by applying a clamp across the renal pedicle for
10 minutes. The kidneys were rapidly removed and snap frozen in
liquid nitrogen for subsequent biochemical analysis. Control
kidneys (no ischemia) were removed rapidly without being subject
to ischemia.
Induction of renal ischemia-reperfusion injury
After being anesthetized (ketamine 85 mg/kg, xylazine 15 mg/
kg) mice were placed on a heating pad to maintain their core body
temperature at 37uC during surgery. A midline abdominal incision
was made and the renal pedicles were bluntly dissected. After right
nephrectomy, a microvascular clamp (Roboz, Rockville, MD) was
placed on the left renal pedicle for either 18 or 20 min while the
animal was kept at 37uC in an incubator and well hydrated. The
clamp was then removed and the kidney observed to confirm
complete reperfusion. The surgical wounds were then sutured in
two layers with 5–0 silk. Warm normal saline (100 mL/kg) was
instilled into the peritoneal cavity during the procedure. Mice were
allowed to recover for 2 hr under a heating lamp and then kept on
a heating pad. After 24 hr of reperfusion, the mice were
euthanized, blood was taken and kidney samples were obtained
for histological analysis.
Assessment of renal function
Whole blood was collected from an inferior vena cava puncture
and sent for biochemical analysis. Serum creatinine level (modified
Jaffe rate reaction) and urea level weremeasured by the Department
of Pathology at the St. Vincent’s Hospital Melbourne (Olympus AU
2700, Integrated Science, Chatswood, NSW, Australia).
Preparation of kidney lysates
Lysates of mouse kidney were prepared by homogenization into
2 ml of homogenization buffer (20 mM Tris?HCl, pH 8.0, 2 mM
MgCl2, 200 mM sucrose, 1% Triton X-100, 50 mM NaF, and
protease inhibitors 2 mM PMSF, 1 mM leupeptin, 0.2 mM
aprotonin, 1 mM benzamidine, and 1 mM AEBSF) and centri-
fugation (15,000 g, 5 min). The resultant supernatant was further
clarified by high-speed centrifugation (75,000 g, 30 min).
Immunoprecipitation of AMPK
AMPK was immunoprecipitated by mixing 1 ml a1-AMPK
antibody (1 mg/ml) with 2 mg of kidney lysate at 4uC for 1 hour.
Immunocomplexes were precipitated by mixing the sample with
Protein A beads (20 ml) (Amersham Pharmacia, Uppsala, Sweden)
at 4uC for 30 minutes. After immunoprecipitation the beads were
collected by centrifugation and washed 3 times in ice cold wash
buffer (1% TritonX-100 in PBS) and once in cold PBS. Reducing
Laemmli sample buffer (20 ml) was added to the beads, which were
then heated to 95uC for 4 minutes prior to analysis by SDS-PAGE
and Western blot.
Western Blotting
Samples were separated by SDS-PAGE and electrically trans-
ferred to a PVDF membrane. The membrane was blocked in 5%
casein in Tris-buffered saline (TBS) for 1 hour and then incubated in
primary antibody overnight. After washing in TBS 0.05% Tween20
(TBS-T) the membrane was then incubated for 30 minutes in
secondary antibody at 1/2500 dilution. After further washing,
immunoreactive proteins were detected by enhanced chemilumi-
nescence with the SuperSignal Chemiluminescent System (Perkin
Elmer). Western blots were quantified by densitometry (Scion Image
for Windows, Scion Corporation, Frederick, Maryland).
AMPK Activity Assay
AMPK activity was measured as previously described [15].
Briefly, AMPK was immunoprecipitated from kidney lysates and
then a phosphorylation reaction was performed in kinase assay
buffer [50 mMHepes, pH 7.5, 10 mM MgCl2, 5% glycerol,
1 mM DTT, 0.05% Triton X-100, 250 mM (c-32P)-ATP
(500 cpm/pmole), 100 mM ADR1 peptide substrate] [21] to
measure AMPK activity (pmol/mg/min).
Renal Histology and Scoring
Ten percent formalin-fixed and paraffin-embedded kidney
tissue sections (4 mm) were stained with hematoxylin-eosin. Three
high-power fields in each of the cortex, corticomedullary junction
and medulla were assessed in a blinded fashion (DP). Scores from
the 3 high power fields were then averaged. The degree of tubular
necrosis was graded and a modified scoring system was used as
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previously described [22]: 0, normal kidney; 1, minimal necrosis
(,10% involvement); 2, mild necrosis (10%–35% involvement); 3,
moderate necrosis (36%–75% involvement); and 4, severe necrosis
(.75% involvement).
Immunohistochemistry
Tissue was immersion-fixed in 4% paraformaldehyde (BDH,
Poole, UK), processed, and embedded in paraffin. 4 mm thick
paraffin sections were incubated overnight with the anti-MIF
antibody (1 mg/ml) at 4uC. Mouse IgG was detected using the
mouse peroxidase-antiperoxidase (PAP) technique, comprising a
goat anti-mouse Ig (Dako, Carpinteria, CA) diluted at 1/100,
followed by mouse PAP (Dako) diluted 1/100. Peroxidase labelling
was revealed using the liquid DAB substrate-chromagen system
(Dako). Sections were counterstained with hematoxylin.
Statistics
Statistics were performed using GraphPad Prism Version 4.03
(GraphPad Software, Inc; San Diego, CA). Data are presented as
mean 6 SD. Unless otherwise stated, data were analyzed by
ANOVA; if significant, Bonferroni’s test for multiple comparisons
was used. P values less than 0.05 were deemed significant.
Results
AMPK activation by acute renal ischemia in wild type,
AMPK-a12/2 and AMPK-b12/2 mice
To determine the potential usefulness of AMPK knockout mice
for studying the role of AMPK activation by acute renal ischemia,
AMPK activity after renal ischemia was studied in mice deficient
for either the a1 or b1 subunit. The phenotypes of the AMPK-
a12/2 and AMPK-b12/2 mice have been described previously
[19,23]. Acute renal ischemia was induced by occluding the renal
pedicle for 10 minutes and AMPK activity was measured after
immunoprecipitations for the a1 and a2 subunits. Acute renal
ischemia activated both a1-AMPK (3.2-fold, P,0.001) and a2-
AMPK activity (2.5-fold, P,0.001) in WT mice (n = 12–16)
(Fig. 1). In kidneys from AMPK-a12/2 mice, basal a1-AMPK
activity was reduced by 70% and no increase in a1-AMPK activity
was seen with ischemia (Fig. 1A). The observation of residual a1-
AMPK activity remaining detectable in AMPK-a12/2 mice
indicates some background activity measured by the ADR-1
activity assay that is not accounted for by AMPK, as the AMPK-
a12/2 mice are totally deficient for the a1 chain. In kidneys of
AMPK-a12/2 mice, a2-AMPK activity and activation by acute
ischemia was preserved and not different from WT (Fig. 1B).
In AMPK-b12/2 mice non-ischemic (basal) total (a1 plus a2)
AMPK activity compared to WT was reduced from 16.16
4.8 pmol/mg/min to 4.963.5 pmol/mg/min (70% reduction,
P= 0.001) (Fig. 1C&D). In these mice the reduction in basal a1-
AMPK activity was 86% (P,0.001); compared with a 43%
reduction for a2-AMPK activity (P = 0.057). a1-AMPK activity
after acute renal ischemia was reduced in AMPK-b12/2 mice
compared with WT (10.867.5 vs 31.0613.1 pmol/mg/min, 65%
reduction, P= 0.002) (Fig. 1C). In addition, a2-AMPK activity was
also reduced in AMPK-b12/2 mice after acute renal ischemia
compared with WT (3.861.0 vs 12.062.6 pmol/mg/min, 68%
reduction, P,0.001) (Fig. 1D). Whilst AMPK activity was
significantly reduced in AMPK-b12/2 mice, in these mice there
Figure 1. AMPK activation by acute renal ischemia in wild type, AMPK-a12/2 and AMPK-b12/2mice. Lysates (1 mg protein) from control
(% no ischemia) and ischemic (& 10 min ischemia) kidneys of WT (C57Bl/6), AMPK-a12/2 and AMPK-b12/2 mice were immunoprecipitated with
antibodies specific for the a1 and a2 AMPK catalytic subunits (n = 6–8 per group). Results are shown as mean 6 SD. In WT mice AMPK activity was
increased by acute renal ischaemia (P,0.001). In AMPK-b12/2 mice, AMPK activity after acute renal ischaemia was reduced compared to WT for both
AMPK-a1 (P,0.001) and AMPK-a2 (P,0.001) isoforms. In AMPK-a12/2 mice there was no activation of AMPK-a1 by acute renal ischemia, whereas
AMPK-a2 was activated by acute renal ischemia (P,0.01) by an amount not different to WT. * P,0.001, ** P,0.01.
doi:10.1371/journal.pone.0029887.g001
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was still a 7.0-fold relative increase in a1-AMPK activity after
acute renal ischemia (P= 0.013) (Fig. 1C). In contrast, for the
AMPK-b12/2 mice no increase in AMPK-a2 activity was seen
after acute renal ischemia (Fig. 1D).
Renal expression of activated AMPK in wild type and
AMPK-b12/2 mice
To further quantify the reduction of renal AMPK activity in
AMPK-b12/2 mice, kidney lysates from WT and b12/2 were
analyzed by Western blot for expression of the activated form of
AMPK, which is phosphorylated at aThr172 in the activation loop
of the catalytic subunit. In kidneys from AMPK-b12/2 mice,
phospho-aThr172 expression was profoundly reduced, although
not absent (Fig. 2 A & B). By densitometry analysis expression of
activated AMPK was reduced by 96% (P,0.001) (Fig. 2C). After
probing for phospho-aThr172 the membrane was stripped and re-
blotted for the a1 and a2 catalytic subunits, which were also both
markedly reduced in AMPK-b12/2 mice (Fig. 2A). Western blot
analysis for the scaffolding b-subunits confirmed the absence of b1
expression in the AMPK-b12/2 kidney (Fig. 2B). Of note, the b2
subunit isoform was also detectable, and was not different between
WT and AMPK-b12/2 (Fig. 2B).
Severity of renal IRI in wild type and AMPK-b12/2 mice
Given the significant reductions in a1 and a2 AMPK
expression, AMPK activity and activation in the AMPK-b12/2
mice this strain was selected for further study. Unilateral renal IRI
was induced in both WT and AMPK-b12/2 mice for 18 or
20 minutes. Control animals underwent a sham procedure. There
was no difference in procedure related mortality between the WT
and AMPK-b12/2 mice. The severity of renal IRI was
determined by measurement of serum urea and creatinine at 24-
hours (Fig. 3). After 20 minutes of renal ischemia-reperfusion
serum urea and creatinine were increased at 24 hours in both WT
and AMPK-b12/2 mice (P,0.001). Importantly, however, no
differences in serum urea and creatinine level were observed
between WT and AMPK-b12/2 mice.
The severity of renal IRI was also assessed by measurement of
the histological injury score 24-hours after reperfusion in cortex,
corticomedullary junction (CMJ) and medulla (Fig. 4). The more
severe injury occurred at the CMJ (Fig. 4C). No differences in the
severity of injury were seen between AMPK-b12/2 mice and WT
mice.
AMPK activation and phosphorylation after acute renal
ischemia in MIF2/2 and wild type mice
To determine whether MIF contributes to AMPK activation by
acute renal ischemia studies were performed in MIF2/2 mice.
Immunohistochemical staining confirmed widespread constitutive
renal MIF expression, with the predominant site of expression
being tubular epithelium (Fig. 5A). The specificity of MIF staining
was confirmed by the absence of staining in the MIF2/2 mice.
Western blot analysis confirmed that MIF was expressed in WT
but absent in the kidneys of MIF2/2 mice (Fig. 5B). There was
no difference in expression of the MIF receptor CD74 between
WT and MIF2/2 mice (Fig. 5B). Renal MIF expression was
unchanged after 10 minutes of acute renal ischaemia (Fig. 5C).
There was no difference in AMPK expression or subunit pattern
between MIF2/2 and WT mice, with the a1, a2, b1, b2, c1 and
c2 all being expressed (Fig. 5D). The b1 subunit was much more
easily detectable than the b2 subunit in the mouse kidney by
Western blot, consistent with the earlier finding that b1 is the
predominant AMPK scaffolding subunit in the mouse kidney.
After 10 minutes of acute ischemia, renal a1-AMPK activity was
increased 3.85-fold inWTmice (P,0.001) and 2.79-fold inMIF2/2
mice (P,0.001) (Fig. 6A). Similarly, renal a2-AMPK activity was
increased by ischemia 3.11-fold in WT mice (P,0.001) and 3.16-
fold in MIF2/2mice (P,0.001) (Fig. 6B). There were no differences
in renal a1-AMPK or a2-AMPK activity betweenWT andMIF2/2
mice at baseline or after renal ischemia. Activation of AMPK after
acute renal ischemia was associated with increased activating
phosphorylation of AMPK-aThr172 both in WT and MIF2/2 with
no difference being observed between the two groups (Fig. 6C&D).
Interestingly, increased phosphorylation of AMPK-aSer485 was also
observed in both WT and MIF2/2 after acute renal ischemia
(Fig. 6C&D), although the role of phosphorylation of AMPK at this
site remains unclear [24]. Increased phosphorylation at aThr172 and
Figure 2. Renal expression of activated AMPK is markedly
reduced in AMPK-b12/2 mice. A and B. Lysate from WT and AMPK-
b12/2 kidneys were analyzed by Western blot for the activated form of
AMPK, phosphorylated at Thr172 of the catalytic (a) subunit. The
membrane was stripped and reblotted to determine expression of the
catalytic (a1 and a2) (A) and scaffolding (b1 and b2) (B) subunits of
AMPK. Expression of b-actin was determined to confirm even sample
loading. C. Expression of activated (phospho-aThr172) in kidneys from
WT and AMPK-b12/2 mice was quantified by densitometry using
arbitrary units (n = 6 per group). Densitometry for phospho-aThr172 was
corrected for b-actin. * P,0.001 by unpaired t test.
doi:10.1371/journal.pone.0029887.g002
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aSer485 after acute ischemia was observed both by Western blot of
samples immunoprecipitated for a1-AMPK (Fig. 6C) and Western
blot of whole kidney lysate (Fig. 6D). Activation of AMPK by acute
renal ischaemia in WT and MIF2/2 was associated with increased
phosphorylation of the AMPK substrate acetyl-CoA carboxylase at
Ser79 (ACC-Ser79) (Fig. 6E), which is known to regulate fatty acid
synthesis and oxidation [2]. ACC was observed as a single band with
a molecular weight of 250 kDa consistent with the cytoplasmic
ACC1 isoform. Since a previous study in the heart has reportedMIF
to augment ischemic AMPK activation by signaling through CD74
[6], CD74 expression was compared between kidney and heart
(Fig. 6F). In the kidney the level of CD74 expression appeared
substantially lower than was seen in the heart (Fig. 6F). CD74
expression did not change in the kidney in response to acute
ischemia.
Discussion
The lack of effect of deletion of AMPK-b1 on renal IRI in the
present study contrasts with a previous study that found the
AMPK activator AICAR, in combination with N-acetylcysteine,
attenuated IRI in a canine model of autologous renal transplan-
tation [25]. In that study, however, it is unclear whether the
protection against IRI was mediated by AICAR or N-acetylcys-
teine and also whether any effect of AICAR was mediated by
activation of AMPK or other non-specific effects. More recently,
Seo-Mayer et al. have reported that pre-activation of AMPK
before renal IRI by the diabetes drug metformin reduced both
histological injury and the level of the urinary biomarker
neutrophil gelatinase associated lipocalin (NGAL) [26]. This study
also found, consistent with our results, that metformin pre-
activation did not affect the increase in serum urea and creatinine
observed after renal IRI, suggesting that its effects did not protect
against the overall severity of renal injury [26].
Cell culture studies examining the effect of AMPK activation on
apoptosis of renal cells in culture have produced variable results.
Han et al. found that AMPK activation increased hypertonicity-
induced apoptosis in medullary interstitial cells [27]. In contrast,
Liebarthal et al found in cultured proximal tubular cells that
activation of AMPK is protective against apoptosis induced by
Figure 3. Severity of renal ischemia-reperfusion injury in wild type and AMPK-b12/2mice assessed by serum urea and creatinine at
24 hours post IR. Serum urea (A) and creatinine (B) were measured 24 hours post renal IR for 18 or 20 minutes in WT and AMPK-b12/2 mice (n = 6–
13 per group). Results are shown as mean6 SD. * P,0.001, ** P,0.01. No significant differences between WT and AMPK-b12/2 mice were observed.
doi:10.1371/journal.pone.0029887.g003
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metabolic stress by an Akt dependant mechanism [28]. In fact it is
well known that AMPK activation can have either anti-apoptotic
or pro-apoptotic effects depending on the cell type and the
physiological situation [29]. It is problematic, therefore, to predict
from cell culture studies the effect AMPK activation on the
severity of kidney injury in vivo. The finding of the present study
that AMPK activation appeared to have a neutral effect in renal
IRI suggest that any possible effect of AMPK on renal cell
apoptosis in response to ischaemia appears to be not having an
effect on the overall severity of kidney injury and renal
dysfunction.
The finding that reduced AMPK activation does not alter the
severity of renal IRI contrasts with studies of myocardial ischemia,
where activation of AMPK appears protective [3,6]. Further,
activation of AMPK in the ischemic brain appears harmful
[10,11]. Our data suggest a neutral effect of AMPK activation
within the kidney in a model of warm IRI. The beneficial effects of
AMPK in ischemia have generally been attributed to its effect on
energy homeostasis, which act to prevent ATP depletion and
subsequent apoptosis [3]. The mechanism by which AMPK
activation by ischemia can exacerbate injury, as seen in stroke, is
less clear but has been proposed to involve lactic acidosis, glucose
transporter upregulation, and activation of autophagy [30]. It has
also been proposed that in some circumstances activation of
AMPK by myocardial ischaemia can be harmful, possibly by
worsening intracellular acidosis [31]. Activation of AMPK in
response to ischemia is likely to regulate multiple substrates and
pathways, some of which may be protective and others of which
may be harmful.
The principle finding of this study is that the severity of IRI was
unaltered in AMPK-b12/2 despite the fact that basal AMPK
expression, activity and activation were significantly reduced. This
suggests that AMPK is unlikely to have a vital protective role in
renal IRI. A limitation of the present study, however, is that, while
significantly and substantially reduced, a low level of AMPK
activity and activation was still detectable in kidneys from AMPK-
b12/2 mice. The AMPK activity data estimates a reduction of
renal AMPK activity in the AMPK-b12/2 mice of approximately
70%, whereas the Western blot data suggests a more profound
96% reduction in the expression of activated AMPK. This
Figure 4. Histological injury 24 hours after renal ischemia-reperfusion injury in wild type and AMPK-b12/2mice. IRI was performed for
20 minutes and the severity of injury was assessed by histology. A. Histological appearance at 24 hours following 20 mins IRI in WT and b12/2 mice.
Images shown are from the region of the corticomedullary junction (CMJ). 2006magnification. The severity of histological injury at 24-hours was
quantified in cortex (B), CMJ (C) and medulla (D) as described in methods. No differences were seen between WT and b12/2 mice. n = 7 for WT and 6
for b12/2.
doi:10.1371/journal.pone.0029887.g004
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discrepancy might be explained, at least in part, by the observation
that the AMPK activity assay does detect a low but measurable
level of non-specific background activity that is not altered by the
presence or absence of AMPK expression. Interestingly, while
AMPK activity was reduced in AMPK-b12/2 mice, the relative
level of AMPK activation with ischemia was similar in WT and
AMPK-b12/2 mice. The residual AMPK activity and activation
in the AMPK-b12/2 can be explained by expression of the
AMPK-b2 subunit that was detectable, at a proportionally low
level, in the mouse kidney. Interestingly, in the rat kidney b2 has
been observed as the predominant AMPK scaffolding subunit
[32,33], contrasting with the findings seen here in the mouse
kidney where b1 is predominant. Whilst the results of the present
study should be interpreted in the context of the limitation of the
model used at present a total AMPK null kidney is not available.
This is because total AMPK knockout has been found to be
embryonically lethal at day 10.5 post-conception [34]. An
additional consideration is the possibility that there are differences
in the functions of the various AMPK catalytic or regulatory
subunits in the kidney that are presently not known. Further
studies in mice with other disruptions to the AMPK pathway
might provide further insight into the role of AMPK in renal IRI.
In the present study we observed that AMPK activation by
acute renal ischaemia occurred simultaneously with increased
phosphorylation of both AMPK-aThr172 and AMPK-aSer485.
Whilst the role of AMPK-aThr172 phosphorylation in the
activation of AMPK is well-characterized [35], the functional
significance of phosphorylation at the AMPK-aSer485 site, which
exists in the bc binding domain of the a subunit [36], is not well
understood. Whilst two studies have reported that phosphorylation
of AMPK-aSer485 might in fact be inhibitory [37,38], this is
contradicted by the observation that the activating mutation of this
site to aspartate is still robustly activated by liver purified AMPK-
kinase [24]. The kinase(s) responsible for AMPK-aSer485 have not
been extensively studied, although both insulin and hepatitis C
have been reported to inhibit AMPK activation by mediating
phosphorylation of this site by Akt/PKB [37,38]. In addition
however, AMPK-aSer485 is reported to be phosphorylated by liver
purified AMPK-kinase, but whether this was mediated by LKB1,
CaMKKb or autophosphorylation was not defined [24]. These
Figure 5. MIF and AMPK expression in MIF and WT mice. A. Renal expression of MIF was determined by immunohistochemical staining using
a monoclonal Ab against MIF (ab 7207) in sections from cortex and medulla. To ensure the specificity of staining, immunohistochemistry was
performed on sections from WT (C57Bl/6) and MIF2/2 kidneys. B. Kidney lysates from MIF2/2 and WT mice were analyzed by Western blot with a
mouse monoclonal against MIF. MIF was detected as a single band at 14 kDa. There was no difference in CD74 expression between WT and MIF2/2
mice. Western blotting for b-tubulin was performed to confirm equivalent protein loading. C. MIF expression was analyzed by Western blot from
lysates of control and ischemic (10 mins) kidneys of WT mice. MIF expression was quantified by densitometry of western blot blots control and
ischemic kidneys. n = 7 for both groups. MIF expression was normalized to b-tubulin expression to ensure even loading. Results shown as mean6 SD.
D. Immunoprecipitations were performed from kidney lysates (4 mg protein) of MIF2/2 and WT C57Bl/6 mice with rabbit polyclonal antibodies
against the a1 and a2 catalytic subunits of AMPK. The immunoprecipitated complexes were separated by SDS-PAGE and western blotted with
antibodies against a1, a2, b1, b2, c1 and c2 subunits of AMPK. Blots shown are representative of 3 individually performed experiments.
doi:10.1371/journal.pone.0029887.g005
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apparent inconsistencies might be explained by differences in the
sequences of phosphorylation events. For example, in the study by
Horman et al. where AMPK-aSer485 appears inhibitory, phos-
phorylation of AMPK-aSer485 preceded phosphorylation of
AMPK-aThr172. In contrast, in the present study in which
AMPK-aSer485 phosphorylation appears to occur either after or
simultaneous to AMPK-aThr172 phosphorylation, a marked
increase in AMPK activity was seen despite the fact that
phosphorylation at AMPK-aSer485 was increased.
The finding in the present study that the presence of MIF did
not contribute to activation of AMPK in the ischemic kidney
contrasts with what has been reported in the ischemic heart and
cultured cardiomyocytes [6,16]. We also did not observe any effect
of recombinant MIF on AMPK activity in a kidney cell line (data
not shown). The receptor for MIF has been identified as CD74,
which is the MHC class II invariate chain [39]. Furthermore,
signaling through CD74 appears to mediate MIF induced
activation of AMPK in the heart [6]. Sanchez-Nino et al. have
reported constitutive CD74 expression in the rat kidney, which
was localized to glomeruli and tubules and increased with diabetes
[40]. Furthermore, CD74 was found to be expressed by cultured
podocytes and proximal tubular cells [40]. In the present study we
found to that CD74 was detectable by Western blot of kidney
lysates, but the level of expression was markedly lower than in the
Figure 6. AMPK activation and phosphorylation after acute renal ischemia in MIF2/2 mice. Lysates (1 mg protein) from control (% no
ischemia) and ischemic (& 10 min ischemia) kidneys of WT (C57Bl/6) and MIF2/2 mice were immunoprecipitated with antibodies specific for the a1
(A) and a2 (B) AMPK catalytic subunits (n = 10–12 per group for a1 and n= 6 for a2). AMPK activity was measured by ADR-1 peptide activity assay.
Results are shown as mean 6 SD. a1-AMPK and a2-AMPK activity were increased several fold after 10 minutes ischemia in WT and MIF2/2 mice
(* P,0.001). There were no differences in a1-AMPK or a2-AMPK activity between WT and MIF2/2 under either control or ischemic conditions. C.
Lysates (1 mg protein) from control (C) and ischemic (Isc) kidneys of WT and MIF2/2 mice were immunoprecipitated with antibodies specific for the
a1 AMPK catalytic subunit and analyzed by Western blotting using antibodies against pAMPKaThr172, pAMPKaSer485 and a1AMPK (blot shown
representative of 4 experiments). D. In addition, whole kidney lysates (50 mg) from the same experiment were separated by SDS-PAGE and analyzed
by Western blot for AMPK phosphorylation at aThr172 and aSer485, with blotting for b-actin as a loading control (blot shown representative of 4
experiments). E. Kidney lysates from this experiment were blotted for inhibitory phosphorylation of ACC at Ser79 and expression of total ACC1 (blot
shown representative of 4 experiments). F. Heart and kidney lysate was blotted for expression of the MIF receptor CD74.
doi:10.1371/journal.pone.0029887.g006
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heart. This observation raises the possibility that the lower CD74
expression seen in the kidney compared to the heart might help
explain the different effects of MIF on AMPK activity between
heart and kidney. At present, however, the explanation for the
difference between the regulation of AMPK by MIF between the
heart and the kidney is not clear. Nonetheless, it is known that
activation of AMPK in response to specific regulators can vary
between different tissues. For example AMPK activity is increased
by leptin in skeletal muscle [41] and reduced by leptin in the
hypothalamus [42]. The two major pathways of AMPK activation
are known to be mediated by an increase in cellular [AMP], acting
via the upstream kinase LKB1 [43], or an increase in cellular [Ca
2+], acting via the upstream kinase CaMKKb [44]. Whilst acute
renal ischemia is known to acutely increase both cellular [AMP]
and [Ca2+] [45], it is not known whether activation of AMPK by
acute renal ischemia occurs predominantly downstream of LKB1
or CaMKKb. The present study shows, however, that the
pathways of AMPK activation by acute renal ischemia involve
phosphorylation of AMPK-aThr172 by upstream kinase(s) and this
is not influenced by the presence or absence of MIF.
In summary, this study found that AMPK is activated in
response to acute renal ischemia and that activation is associated
with phosphorylation of AMPK at aThr172 and aSer485 and
inhibitory phosphorylation of ACC-Ser79. Significant constitutive
expression of MIF in tubular epithelium was found, but there was
no difference in AMPK activation by acute renal ischemia
between WT and MIF2/2 mice. Expression of AMPK and
activation of AMPK by acute renal ischemia was markedly
attenuated in AMPK-b12/2 mice. Despite this there was no
difference in the severity of renal IRI, as measured biochemically
or histologically, between AMPK-b12/2 and WT mice. The lack
of effect of reduced AMPK activation on the outcome of renal IRI
suggests that renal protection in situations of severe energy stress is
unlikely to be a critical function of AMPK in the kidney. This
supports a more general view that the primary role of AMPK in
the kidney is likely to be to detect and respond to more minor
perturbations of cellular energy status that occur within the
context of normal renal physiology.
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